LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Multifaceted Intervention Reduces In-Patient Laboratory Costs

By LabMedica International staff writers
Posted on 16 Feb 2016
Image: A phlebotomist examining a blood sample to be used for multiple tests ordered by the physician (Photo courtesy of University of Utah Medical Center).
Image: A phlebotomist examining a blood sample to be used for multiple tests ordered by the physician (Photo courtesy of University of Utah Medical Center).
Image: Photomicrograph of a blood smear, part of the complete blood count (Photo courtesy of the University of Utah Medical Center).
Image: Photomicrograph of a blood smear, part of the complete blood count (Photo courtesy of the University of Utah Medical Center).
A tool called Value Driven Outcomes has been developed to reduce superfluous laboratory testing and when integrated into a quality improvement initiative laboratory costs decreased by nearly 10% per visit.

Unnecessary laboratory testing contributes to the estimated USD 910 billion wasted each year in health care in the USA. Beyond costs, laboratory testing is an important patient safety issue. The sheer number of tests ordered can lead to incidental findings that result in unnecessary follow-up testing and potentially harmful interventions, and early morning blood draws can prevent much needed rest. Vulnerable patients can even develop anemia and associated complications from over-testing.

Scientists at the University of Utah Medical Center (Salt Lake City, UT) carried out a retrospective, controlled, interrupted time series (ITS) study to evaluate the impact of a multifaceted laboratory reduction intervention on laboratory costs. Measurements were made of the primary outcomes of laboratory cost per day and per visit. Another measurement was the outcomes of number of basic metabolic panel (BMP), comprehensive metabolic panel (CMP), complete blood count (CBC), and prothrombin time/international normalized ratio tests per day; length of stay (LOS); and 30-day readmissions.

The results of the interventions over a 15-month period were tangible. An intervention group of 6,310 hospitalist patient visits were compared to a control group of 25,586 non-hospitalist visits. The interventions reduced the mean cost per day for laboratory testing from USD 138 to USD 123 and the mean cost per visit decreased from USD 618 to USD 558. There was also a significant reduction in laboratory cost per day, laboratory cost per visit, and the number of tests per day.

The authors concluded that a multifaceted approach, including education, rounding checklist implementation, cost feedback, and financial incentives, to laboratory reduction demonstrated a significant reduction in laboratory cost per day and per visit, as well as common tests per day at a major academic medical center.

Peter Yarbrough, MD, an assistant professor of internal medicine and lead author of the study, said, “Frequently, patients do need labs every morning, but that can create a culture where you're ordering tests without really thinking about what you're going to do with the results. Prior to VDO, we never had cost information. Most of the tests don't cost very much, but their numbers were so high that the total cost became significant.” The study was published on February 4, 2016, in the Journal of Hospital Medicine.

Related Links:

University of Utah Medical Center


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Urine Chemistry Control
Dropper Urine Chemistry Control

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more